Zhejiang Starry Pharm Co Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical raw materials in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iomeprol, ioversol, and gadoben… Read more
Zhejiang Starry Pharm Co Ltd (603520) - Net Assets
Latest net assets as of September 2025: CN¥2.61 Billion CNY
Based on the latest financial reports, Zhejiang Starry Pharm Co Ltd (603520) has net assets worth CN¥2.61 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.85 Billion) and total liabilities (CN¥3.24 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.61 Billion |
| % of Total Assets | 44.56% |
| Annual Growth Rate | 18.13% |
| 5-Year Change | 41.28% |
| 10-Year Change | 475.59% |
| Growth Volatility | 29.33 |
Zhejiang Starry Pharm Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Zhejiang Starry Pharm Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Zhejiang Starry Pharm Co Ltd (2011–2024)
The table below shows the annual net assets of Zhejiang Starry Pharm Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.63 Billion | +49.78% |
| 2023-12-31 | CN¥1.76 Billion | -0.70% |
| 2022-12-31 | CN¥1.77 Billion | -20.02% |
| 2021-12-31 | CN¥2.21 Billion | +18.76% |
| 2020-12-31 | CN¥1.86 Billion | +81.27% |
| 2019-12-31 | CN¥1.03 Billion | +11.46% |
| 2018-12-31 | CN¥922.96 Million | +5.79% |
| 2017-12-31 | CN¥872.44 Million | +5.49% |
| 2016-12-31 | CN¥827.01 Million | +80.69% |
| 2015-12-31 | CN¥457.70 Million | +5.92% |
| 2014-12-31 | CN¥432.13 Million | +11.92% |
| 2013-12-31 | CN¥386.11 Million | +14.64% |
| 2012-12-31 | CN¥336.81 Million | +11.60% |
| 2011-12-31 | CN¥301.81 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Zhejiang Starry Pharm Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 800.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥387.10 Million | 14.73% |
| Common Stock | CN¥438.41 Million | 16.68% |
| Other Comprehensive Income | CN¥179.00 Million | 6.81% |
| Other Components | CN¥1.62 Billion | 61.78% |
| Total Equity | CN¥2.63 Billion | 100.00% |
Zhejiang Starry Pharm Co Ltd Competitors by Market Cap
The table below lists competitors of Zhejiang Starry Pharm Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hubei Radio and Television Information Network Co Ltd
SHE:000665
|
$434.69 Million |
|
Sudarshan Chemical Industries Limited
NSE:SUDARSCHEM
|
$434.72 Million |
|
Anhui Xinli Finance Co Ltd
SHG:600318
|
$434.82 Million |
|
Zhejiang Xinao Textiles Inc
SHG:603889
|
$434.88 Million |
|
Qingmu Digital Technology Co.Ltd.
SHE:301110
|
$434.39 Million |
|
Jupiter Fund Management Plc
PINK:JFHHF
|
$434.30 Million |
|
MANDARIN ORIENTAL DL-05
F:1C4
|
$434.24 Million |
|
General Interface Solution GIS Holding Ltd
TW:6456
|
$434.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhejiang Starry Pharm Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,752,604,843 to 2,628,155,919, a change of 875,551,076 (50.0%).
- Net loss of 49,098,979 reduced equity.
- Dividend payments of 128,424,731 reduced retained earnings.
- Other comprehensive income increased equity by 179,875,636.
- Other factors increased equity by 873,199,150.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-49.10 Million | -1.87% |
| Dividends Paid | CN¥128.42 Million | -4.89% |
| Other Comprehensive Income | CN¥179.88 Million | +6.84% |
| Other Changes | CN¥873.20 Million | +33.22% |
| Total Change | CN¥- | 49.96% |
Book Value vs Market Value Analysis
This analysis compares Zhejiang Starry Pharm Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.54x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.29x to 1.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥1.19 | CN¥9.88 | x |
| 2012-12-31 | CN¥1.35 | CN¥9.88 | x |
| 2013-12-31 | CN¥1.55 | CN¥9.88 | x |
| 2014-12-31 | CN¥1.70 | CN¥9.88 | x |
| 2015-12-31 | CN¥1.79 | CN¥9.88 | x |
| 2016-12-31 | CN¥2.64 | CN¥9.88 | x |
| 2017-12-31 | CN¥2.59 | CN¥9.88 | x |
| 2018-12-31 | CN¥2.72 | CN¥9.88 | x |
| 2019-12-31 | CN¥3.03 | CN¥9.88 | x |
| 2020-12-31 | CN¥5.46 | CN¥9.88 | x |
| 2021-12-31 | CN¥6.36 | CN¥9.88 | x |
| 2022-12-31 | CN¥5.16 | CN¥9.88 | x |
| 2023-12-31 | CN¥5.15 | CN¥9.88 | x |
| 2024-12-31 | CN¥6.42 | CN¥9.88 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhejiang Starry Pharm Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.87%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2.09%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 2.30x
- Recent ROE (-1.87%) is below the historical average (10.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 22.95% | 13.34% | 0.70x | 2.46x | CN¥38.12 Million |
| 2012 | 10.84% | 6.23% | 0.70x | 2.50x | CN¥2.76 Million |
| 2013 | 16.74% | 9.28% | 0.68x | 2.65x | CN¥25.62 Million |
| 2014 | 16.08% | 10.28% | 0.57x | 2.73x | CN¥25.60 Million |
| 2015 | 15.65% | 9.91% | 0.47x | 3.36x | CN¥24.89 Million |
| 2016 | 9.40% | 11.31% | 0.36x | 2.34x | CN¥-4.89 Million |
| 2017 | 9.70% | 11.69% | 0.35x | 2.35x | CN¥-2.60 Million |
| 2018 | 10.51% | 10.52% | 0.29x | 3.44x | CN¥4.57 Million |
| 2019 | 17.11% | 13.01% | 0.38x | 3.50x | CN¥70.75 Million |
| 2020 | 13.09% | 17.46% | 0.31x | 2.42x | CN¥56.38 Million |
| 2021 | 14.89% | 16.19% | 0.41x | 2.25x | CN¥106.26 Million |
| 2022 | -4.07% | -3.37% | 0.40x | 3.00x | CN¥-248.45 Million |
| 2023 | 2.52% | 2.01% | 0.40x | 3.15x | CN¥-131.03 Million |
| 2024 | -1.87% | -2.09% | 0.39x | 2.30x | CN¥-311.91 Million |
Industry Comparison
This section compares Zhejiang Starry Pharm Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhejiang Starry Pharm Co Ltd (603520) | CN¥2.61 Billion | 22.95% | 1.24x | $434.63 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |